Edition:
United States

Shionogi & Co Ltd (4507.T)

4507.T on Tokyo Stock Exchange

6,156JPY
1:51am EDT
Change (% chg)

¥-55 (-0.89%)
Prev Close
¥6,211
Open
¥6,207
Day's High
¥6,218
Day's Low
¥6,142
Volume
822,200
Avg. Vol
1,172,065
52-wk High
¥6,465
52-wk Low
¥5,200

Latest Key Developments (Source: Significant Developments)

GlaxoSmithKline Says Gets Positive CHMP Opinion For Juluca In Europe
Friday, 23 Mar 2018 07:21am EDT 

March 23 (Reuters) - GlaxoSmithKline Plc ::VIIV - CHMP POSITIVE OPINION FOR JULUCA IN EUROPE.‍VIIV HEALTHCARE GAINS CHMP POSITIVE OPINION FOR JULUCA (DOLUTEGRAVIR/RILPIVIRINE) IN EUROPE​.FINAL EC DECISION ON EUROPEAN APPROVAL FOR DOLUTEGRAVIR/RILPIVIRINE IS ANTICIPATED TOWARDS END OF Q2 OF 2018.  Full Article

GSK Says ViiV Healthcare Reports Positive Dolutegravir Data
Monday, 5 Mar 2018 12:01pm EST 

March 5 (Reuters) - Glaxosmithkline Plc ::GLAXOSMITHKLINE PLC - VIIV HEALTHCARE ANNOUNCES POSITIVE NEW DOLUTEGRAVIR DATA FOR TREATMENT OF PEOPLE LIVING WITH HIV CO-INFECTED WITH TUBERCULOSIS.GLAXOSMITHKLINE PLC - DOLUTEGRAVIR WHEN ADMINISTERED AT 50MG TWICE-DAILY WITH DUAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, WAS EFFECTIVE.GLAXOSMITHKLINE PLC - DOLUTEGRAVIR WAS WELL-TOLERATED IN HIV/TB CO-INFECTED ADULTS RECEIVING RIFAMPIN-BASED TB THERAPY.  Full Article

Shionogi Announces FDA NDA, EMA MAA Acceptances For Lusutrombopag
Monday, 26 Feb 2018 11:22am EST 

Feb 26 (Reuters) - Shionogi & Co Ltd <4507.T>::SHIONOGI ANNOUNCES FDA NEW DRUG APPLICATION (NDA) AND EMA MARKETING AUTHORIZATION APPLICATION (MAA) ACCEPTANCES FOR LUSUTROMBOPAG (S-888711).SHIONOGI & CO LTD - PRESCRIPTION DRUG USER FEE ACT DATE FOR AN FDA DECISION FOR LUSUTROMBOPAG IS AUGUST 26, 2018.  Full Article

Shionogi says ViiV Healthcare files patent infringement litigation against Gilead Sciences over bictegravir
Thursday, 8 Feb 2018 02:06am EST 

Feb 8 (Reuters) - Shionogi & Co Ltd <4507.T>:Says it announced that ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, has filed patent infringement litigation against Gilead Sciences Inc. over bictegravir in the United States and Canada.The United States case is filed in the U.S. District Court for the District of Delaware and the patent is U.S patent No. 8,129,385.The Canadian case is filed in the Canadian Federal Court in Toronto and the patent is Canadian Patent No. 2,606,282..  Full Article

R&I affirms Shionogi & Co Ltd's rating at "A+" and says stable outlook-R&I
Friday, 15 Dec 2017 01:58am EST 

Dec 15 (Reuters) - Shionogi & Co Ltd <4507.T> ::Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+" -R&I.Rating outlook stable -R&I.  Full Article

Shionogi to repurchase shares and retire treasury shares
Monday, 27 Nov 2017 01:13am EST 

Nov 27 (Reuters) - Shionogi & Co Ltd <4507.T>:Says it will repurchase up to 4.8 million shares, representing 1.5 percent of outstanding.Says share repurchase price at up to 30 billion yen in total.Says repurchase period from Dec. 1 to Feb. 28, 2018.Says it will retire 5 million shares of its common stock on March 12, 2018 .  Full Article

UMN Pharma says business and capital alliance with Shionogi
Monday, 30 Oct 2017 11:37pm EDT 

Oct 31 (Reuters) - UMN Pharma Inc <4585.T>:Says it signed business and capital alliance agreement with Shionogi & Co Ltd <<<4507.T>>> on Oct. 31 .Says two entities will mainly cooperate on establishment of technological basis for drug discovery related to preventive vaccines against infectious diseases .Says it will issue 600,000 shares and first series convertible bonds with subscription warrants to Shionogi & Co Ltd, to raise 1.64 billion yen in total .Payment date on Nov. 16 .  Full Article

Shionogi and Purdue Pharma announce U.S availability of Symproic (naldemedine)
Thursday, 12 Oct 2017 08:01am EDT 

Oct 12 (Reuters) - Shionogi & Co Ltd <4507.T>::Shionogi inc - co, Purdue Pharma L.P. announce that Symproic (naldemedine) 0.2 mg tablets are now available throughout United States​.Shionogi - FDA ‍approved Symproic as once-daily oral tablet for treatment of opioid-induced constipation in adult patients with chronic non-cancer pain​.  Full Article

Shionogi says Lusutrombopag met primary, secondary endpoints in phase 3 study​‍​
Monday, 25 Sep 2017 09:02am EDT 

Sept 25 (Reuters) - Shionogi & Co Ltd <4507.T>‍​:Shionogi & Co Ltd - ‍ Lusutrombopag met primary and all pre-specified important secondary endpoints in a global phase 3 study​.Shionogi & Co Ltd - ‍Lusutrombopag was generally well tolerated, with adverse events deemed treatment-related​.Shionogi & Co Ltd - Lusutrombopag demonstrated superiority to placebo​.Shionogi & Co - ‍based on results from l-plus1 and l-plus2 phase 3 studies, Shionogi has initiated rolling submission of a new drug application to FDA​.Shionogi & Co Ltd - ‍Shionogi plans to present l-plus2 study data at future hepatology and hematology conferences later this year​.  Full Article

Shire and Shionogi announce positive topline results for Intuniv ​
Wednesday, 20 Sep 2017 02:00am EDT 

Sept 20 (Reuters) - SHIRE PLC ::‍SHIRE AND SHIONOGI ANNOUNCE POSITIVE TOPLINE RESULTS FOR INTUNIV EVALUATED IN PHASE 3 CLINICAL TRIAL IN ADULTS WITH ADHD​.  Full Article

FDA approves blood disorder drug made by Japan's Shionogi

The U.S. Food and Drug Administration on Tuesday approved Japan-based Shionogi & Co Ltd's treatment for low blood-platelet count or thrombocytopenia in patients with chronic liver disease.